About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Pediatric Neurology Research group is mainly involved in the study of genetic diseases of the developing nervous system. The main emphasis is on paroxysmal neurological disorders and neuromuscular disorders. A common theme across the different projects, besides the identification of the molecular basis of several of these rare disorders, is the investigation of molecules involved in their pathophysiological mechanisms and the effective translation of these findings into the fields of molecular diagnosis, genetic counselling and newly developed gene or drug therapies.
PMID: 37988272 Journal: BRAIN Year: 2023 Reference: Brain. 2023 Nov 21:awad396. doi: 10.1093/brain/awad396. Impact factor: Publication type: Paper in international publication Authors: Anke, Audny; Beer, Ronny; Bellander, Bo-Michael; Beqiri, Erta; Boxer, Adam L; Buki, Andras; Cabeleira, Manuel; Carbonara, Marco; Chieregato, Arturo; Citerio, Giuseppe et al. DOI: 10.1093/brain/awad396
PMID: 37997866 Journal: Revista Espanola de Quimioterapia Year: 2023 Reference: Rev Esp Quimioter. 2023 Nov;36 Suppl 1:22-24. doi: 10.37201/req/s01.06.2023. Epub 2023 Nov 24. Impact factor: Publication type: Paper in international publication Authors: Boxer, Adam L; de Leon, Jessica; Ezzes, Zoe; Gomez-Andres, David; Gorno-Tempini, Maria Luisa; Grinberg, Lea T; Henry, Maya L; Illan-Gala, Ignacio; Kramer, Joel H; Len, O et al. DOI: 10.37201/req/s01.06.2023
PMID: 38016858 Journal: Anales de pediatria Year: 2023 Reference: An Pediatr (Engl Ed). 2023 Nov 27:S2341-2879(23)00255-7. doi: 10.1016/j.anpede.2023.09.014. Impact factor: Publication type: Paper in international publication Authors: Aceituno-Lopez, Maria Angeles; Asmarats, Luis; Avvedimento, Marisa; Belahnech, Yassin; Bonnet, Guillaume; Camprodon-Gomez, Maria; Cheema, Asim N; De La Torre Hernandez, Jose M; Del-Toro-Riera, Mireia; Esposito, Giovanni et al. DOI: 10.1016/j.anpede.2023.09.014
PMID: 38026127 Journal: Year: 2023 Reference: Front Allergy. 2023 Nov 9;4:1296894. doi: 10.3389/falgy.2023.1296894. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Aceituno-Lopez, Maria Angeles; Alobid, Isam; Camprodon-Gomez, Maria; Del-Toro-Riera, Mireia; Espinosa, Miriam; Gomez de la Fuente, Enrique; Lara-Fernandez, Roser; Luca de Tena, Africa; Marti-Beltran, Sergi; Moreno-Galdo, Antonio et al. DOI: 10.3389/falgy.2023.1296894
The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.
Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.
El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.
